Company news
Fusion Antibodies Plc (LSE:FAB) news
Fusion Antibodies Plc news releases on 6ix. Latest, Oct 5, 2026: Launch of new customer-focused website
Press releases & updates
Launch of new customer-focused website
October 5, 2026
REPLACEMENT: Final Results
September 15, 2026
Grant of Canadian Patent for OptiMAL
September 9, 2026
Notice of acceptance of patent in Australia
August 6, 2026
Notice of allowance of patent in Canada
June 22, 2026
Update on grant-funded DR5 project
June 15, 2026
Exercise of options and total voting rights
June 2, 2026
Grant of patent in Japan
May 11, 2026
Antibody IP transfer agreement
March 30, 2026
Holding(s) in Company
February 4, 2026
Total Voting Rights
January 30, 2026
Issue of Director Shares
January 27, 2026
Placing and Subscription to raise approx £1.4m
January 27, 2026
Update on negotiations with NCI regarding OptiMAL
December 19, 2025
Launch of OptiMAL platform
December 16, 2025
Mammalian Display video
December 11, 2025
Half-year Financial Report
November 24, 2025
Notice of Results
November 21, 2025
OptiMAL Library video
November 13, 2025
OptiMAL® R&D Update
November 3, 2025
Result of AGM
October 16, 2025
AGM statement and H1 trading update
October 16, 2025
Contract win
October 8, 2025
Posting of Annual Report & Notice of AGM
September 19, 2025
OptiMAL R&D Update
September 17, 2025
Belfast investor presentation
September 8, 2025
Final Results
September 4, 2025
Contract Win
August 28, 2025
Contract wins with existing client
August 27, 2025
Investor presentations
August 26, 2025
Grant of U.S. Patent for OptiMAL
August 5, 2025
Issue Notification: US Patent Update
July 24, 2025
Director/PDMR Shareholding
July 11, 2025
Update on U.S. Patent for OptiMAL®
May 22, 2025
Investor presentation
May 8, 2025
Issue of shares to non-executive directors
May 7, 2025
Trading update
May 6, 2025
Approval of grant funding
April 24, 2025
Result of General Meeting
April 7, 2025
Placing to raise approximately £1.17 million
March 18, 2025
Approval of Grant Funding Application
December 4, 2024
Half-year Report
November 19, 2024
AGM statement and trading update
October 8, 2024
Block admission six monthly return
October 2, 2024
Notice of AGM
September 12, 2024
Expansion to OptiMAL collaboration agreement
August 28, 2024
Launch of New Interactive Investor Hub
July 18, 2024
New contract with existing client
May 23, 2024
Fusion Antibodies reports second-half rebound as new commercial strategy pays off
May 9, 2024
Year-end trading statement
April 30, 2024